Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Eplerenone

Nature Reviews Drug Discovery volume 2, pages 177–178 (2003)Cite this article

Abstract

In September 2002, eplerenone (Inspra; Pharmacia), the first selective aldosterone receptor antagonist, was approved by the FDA for the treatment of hypertension. Will it become as successful as established blockbuster drugs that also target the renin–angiotensin–aldosterone system?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Aldosterone antagonism.
Figure 2: Number of cases of hypertension.
Figure 3: Sales for antihypertensive drugs in US $ billion.

References

  1. Mosterd, A. et al. Trends in the prevalence of hypertension, antihypertension therapy, and left ventricular hypertrophy from 1950 to 1999. N. Engl. J. Med. 340, 1221–1227 (1999).

    Article  CAS  Google Scholar 

  2. Zaman, M. A., Oparil, S. & Calhoun, D. A. Drugs targeting the renin–angiotensin–aldosterone system. Nature Rev. Drug Discov. 1, 621–636 (2002).

    Article  CAS  Google Scholar 

  3. McKelvie, R. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD Pilot Study Investigators. Circulation 100, 1056–1064 (1999).

    Article  CAS  Google Scholar 

  4. Rocha, R. & Funder, J. W. The pathophysiology of aldosterone in the cardiovascular system. Ann. NY Acad. Sci. 970, 89–100 (2002).

    Article  CAS  Google Scholar 

  5. McMahon, E. G. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 1, 190–196 (2001).

    Article  CAS  Google Scholar 

  6. Brest, A. N. Spironolactone in the treatment of hypertension: a review. Clin.Ther. 8, 568–585 (1986).

    CAS  Google Scholar 

  7. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).

    Article  CAS  Google Scholar 

  8. de Gasparo, M. et al. Three new spironolactone deriatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650–656 (1987).

    CAS  Google Scholar 

  9. FDA Drug Approvals List [online] (cited 27 Jan 2003). http://www.fda.gov/cder/foi/label/2002/21437lbl.pdf

  10. Quaschning, T. et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37, 801–805 (2001).

    Article  CAS  Google Scholar 

  11. Sica, D. A. Current concepts of pharmacotherapy in hypertension. Eplerenone: a new aldosterone receptor antagonist — are the FDA restrictions appropriate? J. Clin. Hypertens. 4, 441–445 (2002).

    Article  CAS  Google Scholar 

  12. Weinberger, M. et al. Comparison of eplerenone and losartan in patients with low-renin hypertension. Am. J. Hypertens. 15, A24 (2002).

    Article  Google Scholar 

  13. Weber, M. Clinical implications of aldosterone blockade. Am. Heart J. 144, S12–S18 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Decision Resources Intl, 50–51 Russell Square, London, WC1B 4HQ, UK

    Ruth Brown, Jeremy Quirk & Peter Kirkpatrick

Authors
  1. Ruth Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeremy Quirk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruth Brown.

Additional information

Peter Kirkpatrick is Senior Editor of Nature Reviews Drug Discovery. Ruth Brown and Jeremy Quirk are Analysts

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, R., Quirk, J. & Kirkpatrick, P. Eplerenone. Nat Rev Drug Discov 2, 177–178 (2003). https://doi.org/10.1038/nrd1039

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1039

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing